Literature DB >> 17646208

Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes.

Matteo Serino1, Rossella Menghini, Loredana Fiorentino, Roberta Amoruso, Alessandro Mauriello, Davide Lauro, Paolo Sbraccia, Marta L Hribal, Renato Lauro, Massimo Federici.   

Abstract

OBJECTIVE: Tumor necrosis factor (TNF)-alpha is known to affect insulin sensitivity, glucose, and lipid metabolism through alternative and redundant mechanisms at both translational and post-translational levels. TNF-alpha exerts its paracrine effects once the membrane-anchored form is shed and released from the cell membrane. TNF-alpha cleavage is regulated by TNF-alpha converting enzyme (TACE), which regulates the function of several transmembrane proteins, such as interleukin-6 receptor and epidermal growth factor receptor ligands. The role of TACE in high-fat diet (HFD)-induced obesity and its metabolic complications is unknown. RESEARCH DESIGN AND METHODS: To gain insights into the role of TACE in metabolic disorders, we used Tace(+/-) mice fed a standard or high-fat diet for 16 weeks.
RESULTS: We observed that Tace(+/-) mice are relatively protected from obesity and insulin resistance compared with wild-type littermates. When fed an HFD, wild-type mice exhibited visceral obesity, increased free fatty acid and monocyte chemoattractant protein (MCP)1 levels, hypoadiponectinemia, glucose intolerance, and insulin resistance compared with Tace(+/-) mice. Interestingly, Tace(+/-) mice exhibited increased uncoupling protein-1 and GLUT4 expression in white adipose tissue.
CONCLUSIONS: Our results suggest that modulation of TACE activity is a new pathway to be investigated for development of agents acting against obesity and its metabolic complications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17646208     DOI: 10.2337/db07-0360

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  47 in total

Review 1.  ADAM-17: the enzyme that does it all.

Authors:  Monika Gooz
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-04       Impact factor: 8.250

Review 2.  Macrophage recruitment in obese adipose tissue.

Authors:  Y Bai; Q Sun
Journal:  Obes Rev       Date:  2015-01-13       Impact factor: 9.213

3.  ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet-associated Colon Cancer.

Authors:  Reba Mustafi; Urszula Dougherty; Devkumar Mustafi; Fatma Ayaloglu-Butun; Michelle Fletcher; Sarbani Adhikari; Farhana Sadiq; Katherine Meckel; Haider I Haider; Abdurahman Khalil; Joel Pekow; Vani Konda; Loren Joseph; John Hart; Alessandro Fichera; Yan Chun Li; Marc Bissonnette
Journal:  Clin Cancer Res       Date:  2016-08-03       Impact factor: 12.531

4.  A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature.

Authors:  Akira Takaguri; Keita Kimura; Akinari Hinoki; Allison M Bourne; Michael V Autieri; Satoru Eguchi
Journal:  Hypertension       Date:  2011-02-28       Impact factor: 10.190

5.  Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo.

Authors:  Janice M Zabolotny; Young-Bum Kim; Laura A Welsh; Erin E Kershaw; Benjamin G Neel; Barbara B Kahn
Journal:  J Biol Chem       Date:  2008-02-14       Impact factor: 5.157

6.  ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice.

Authors:  Bridget M Ford; Assaad A Eid; Monika Göőz; Jeffrey L Barnes; Yves C Gorin; Hanna E Abboud
Journal:  Am J Physiol Renal Physiol       Date:  2013-05-15

7.  Deficiency of TNFalpha converting enzyme (TACE/ADAM17) causes a lean, hypermetabolic phenotype in mice.

Authors:  Richard W Gelling; Wenbo Yan; Salwa Al-Noori; Aaron Pardini; Gregory J Morton; Kayoko Ogimoto; Michael W Schwartz; Peter J Dempsey
Journal:  Endocrinology       Date:  2008-08-07       Impact factor: 4.736

Review 8.  TNF-alpha and adipocyte biology.

Authors:  William P Cawthorn; Jaswinder K Sethi
Journal:  FEBS Lett       Date:  2007-11-26       Impact factor: 4.124

9.  Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans.

Authors:  A Monroy; S Kamath; A O Chavez; V E Centonze; M Veerasamy; A Barrentine; J J Wewer; D K Coletta; C Jenkinson; R M Jhingan; D Smokler; S Reyna; N Musi; R Khokka; M Federici; D Tripathy; R A DeFronzo; F Folli
Journal:  Diabetologia       Date:  2009-07-25       Impact factor: 10.122

10.  TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1.

Authors:  Marina Cardellini; Rossella Menghini; Eugenio Martelli; Viviana Casagrande; Arianna Marino; Stefano Rizza; Ottavia Porzio; Alessandro Mauriello; Anna Solini; Arnaldo Ippoliti; Renato Lauro; Franco Folli; Massimo Federici
Journal:  Diabetes       Date:  2009-07-06       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.